← Back to Search

Retinal Imaging for Neurodegenerative Disease

Led By Sharon Sharon, MD FACS FASRS
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with neurodegenerative disease (MCI/ADPD/MS/HD)
Be older than 18 years old
Must not have
Eyes that have had intraocular surgery, other than cataract surgery
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 year
Awards & highlights


This trial will use OCTA to develop biomarkers for various neurodegenerative diseases.

Who is the study for?
This trial is for adults with or without neurodegenerative diseases like Alzheimer's, Parkinson's, Multiple Sclerosis, and others. It includes those with mild cognitive issues or traumatic brain injuries. People can't join if they've had certain eye surgeries (except cataract surgery) or have conditions that make it hard to get clear images of their eyes.Check my eligibility
What is being tested?
The study tests non-invasive imaging techniques to examine the retina and choroid in the eye. These include optical coherence tomography (OCT), OCT angiography (OCTA), and ultra-widefield fundus photography to find biomarkers for various neurodegenerative diseases.See study design
What are the potential side effects?
Since this trial involves non-invasive retinal imaging, there are minimal side effects expected. The main risks may include discomfort from bright lights during imaging or temporary vision disturbances after the procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have a neurodegenerative condition like Alzheimer's or Parkinson's.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I have had eye surgery, but not for cataracts.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in average capillary flux index (CFI)
Change in average capillary perfusion density (CPD)
Change in average perfusion density (PD)
+6 more
Secondary outcome measures
Change in retinal vessel fractal dimension
Change in retinal vessel tortuosity
Change in retinal vessel width gradient

Trial Design

2Treatment groups
Experimental Treatment
Group I: ControlsExperimental Treatment1 Intervention
Controls will be recruited from the relatives/attendants of study participants or will be patients themselves and will not have a neurodegenerative disease diagnosis.
Group II: CaseExperimental Treatment1 Intervention
Patients with (MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Down Syndrome primarily focus on managing the symptoms and associated health conditions rather than altering the genetic basis of the disorder. These treatments include early intervention programs, speech therapy, physical therapy, and occupational therapy, which aim to improve cognitive and motor skills. Medical treatments may address specific health issues such as heart defects, thyroid problems, and hearing loss. Non-invasive imaging techniques like Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) are particularly important for Down Syndrome patients as they can help monitor and manage ocular complications, such as cataracts and retinal issues, without the need for invasive procedures. These imaging methods provide detailed views of the retinal and choroidal microvasculature, aiding in early detection and treatment of potential vision problems, thereby improving the quality of life for individuals with Down Syndrome.

Find a Location

Who is running the clinical trial?

University of EdinburghOTHER
462 Previous Clinical Trials
17,112,147 Total Patients Enrolled
1 Trials studying Down Syndrome
200 Patients Enrolled for Down Syndrome
Tan Tock Seng Hospital in SingaporeUNKNOWN
Queens University of Belfast United KingdomUNKNOWN

Media Library

Case Clinical Trial Eligibility Overview. Trial Name: NCT03233646 — N/A
Down Syndrome Research Study Groups: Case, Controls
Down Syndrome Clinical Trial 2023: Case Highlights & Side Effects. Trial Name: NCT03233646 — N/A
Case 2023 Treatment Timeline for Medical Study. Trial Name: NCT03233646 — N/A
~337 spots leftby Dec 2025